Back to Search
Start Over
GSK to acquire Boston-based, clinical-stage biopharma company, IDRx for up to $1.15 billion
- Source :
- PharmaBiz. January 13, 2025
- Publication Year :
- 2025
-
Abstract
- GSK plc and IDRx, Inc. (IDRx) announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.823333925